{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:38:53Z","timestamp":1777599533732,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.urology.2024.09.051","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:24:09Z","timestamp":1727677449000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Differences in Advanced Therapeutic Modalities for Overactive Bladder in the United States by Race"],"prefix":"10.1016","volume":"194","author":[{"given":"Clemens","family":"An","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranjal","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Grutman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhaib","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Chiung Grace","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Clifton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2024.09.051_bib1","first-page":"71","article-title":"Review of the epidemiology of overactive bladder","volume":"8","author":"Eapen","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.urology.2024.09.051_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11884-016-0344-9","article-title":"The burden of overactive bladder on US Public health","volume":"11","author":"Reynolds","year":"2016","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"10.1016\/j.urology.2024.09.051_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.urology.2011.09.010","article-title":"Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study","volume":"79","author":"Coyne","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.09.051_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.urology.2009.06.096","article-title":"Economic costs of overactive bladder in the United States","volume":"75","author":"Ganz","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.09.051_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.urology.2020.04.109","article-title":"Racial and socioeconomic factors influence utilization of advanced therapies in commercially insured OAB patients: an analysis of over 800,000 OAB patients","volume":"142","author":"Syan","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.09.051_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/SPV.0000000000000992","article-title":"Disparity of racial\/ethnic representation in publications contributing to overactive bladder diagnosis and treatment guidelines","volume":"27","author":"Brown","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.urology.2024.09.051_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/SPV.0000000000000100","article-title":"Barriers to urinary incontinence care seeking in White, Black, and Latina women","volume":"21","author":"Willis-Gray","year":"2015","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.urology.2024.09.051_bib8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1089\/bfm.2016.0113","article-title":"Why your ZIP code matters more than your genetic code: promoting healthy outcomes from mother to child","volume":"11","author":"Graham","year":"2016","journal-title":"Breastfeed Med"},{"key":"10.1016\/j.urology.2024.09.051_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.urology.2015.09.025","article-title":"Real-world patterns of care for the overactive bladder syndrome in the United States","volume":"87","author":"Goldman","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.09.051_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City","volume":"40","author":"Hansen","year":"2013","journal-title":"J Behav Health Serv Res"},{"key":"10.1016\/j.urology.2024.09.051_bib11","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.15585\/mmwr.mm7143a3","article-title":"Notes from the field: dispensing of oral antiviral drugs for treatment of COVID-19 by zip code-level social vulnerability - United States, December 23, 2021-August 28, 2022","volume":"71","author":"Sullivan","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.urology.2024.09.051_bib12","series-title":"Communities in Action: Pathways to Health Equity","article-title":"The state of health disparities in the United States","author":"National Academies of Sciences E","year":"2017"},{"key":"10.1016\/j.urology.2024.09.051_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2020.113443","article-title":"The southern rural health and mortality penalty: a review of regional health inequities in the United States","volume":"268","author":"Miller","year":"2021","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.urology.2024.09.051_bib14","unstructured":"Evans B., Zimmerman E., Woolf S., Haley A. Social determinants of health and crime in post-Katrina Orleans Parish: Technical report. Accessed March 21, 2024. \u3008https:\/\/societyhealth.vcu.edu\/media\/society-health\/pdf\/PMReport_Orleans_Parish.pdf\u3009."},{"key":"10.1016\/j.urology.2024.09.051_bib15","first-page":"1442","article-title":"Racial differences in self-reported healthcare seeking and treatment for urinary incontinence in community-dwelling women from the EPI study","volume":"30","author":"Berger","year":"2011","journal-title":"Neurourol\u00a0Urodyn"},{"key":"10.1016\/j.urology.2024.09.051_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.15074","article-title":"Inequities in filled overactive bladder medication prescriptions in the US","volume":"6","author":"Luchristt","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.urology.2024.09.051_bib17","first-page":"1135","article-title":"Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives","volume":"19","author":"Wielage","year":"2016","journal-title":"J\u00a0Med\u00a0Econ"},{"key":"10.1016\/j.urology.2024.09.051_bib18","first-page":"1092","article-title":"Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States","volume":"25","author":"Chen","year":"2022","journal-title":"J\u00a0Med\u00a0Econ"},{"key":"10.1016\/j.urology.2024.09.051_bib19","first-page":"614","article-title":"Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada","volume":"20","author":"Hakimi","year":"2017","journal-title":"J\u00a0Med\u00a0Econ"},{"key":"10.1016\/j.urology.2024.09.051_bib20","unstructured":"Bureau U.C. Health Insurance Coverage in the United States: 2021. Census.gov. Accessed January 15, 2024. \u3008https:\/\/www.census.gov\/library\/publications\/2022\/demo\/p60\u2013278.html\u3009."},{"key":"10.1016\/j.urology.2024.09.051_bib21","unstructured":"Branch B., Conway D. Health Insurance Coverage by Race and Hispanic Origin: 2021. Published online 2021."},{"key":"10.1016\/j.urology.2024.09.051_bib22","first-page":"444","article-title":"Factors associated with long-term use of percutaneous tibial nerve stimulation for management of overactive bladder syndrome","volume":"27","author":"Gordon","year":"2021","journal-title":"Urogynecology"},{"key":"10.1016\/j.urology.2024.09.051_bib23","first-page":"1940","article-title":"Health disparities and access to advanced therapy for overactive bladder","volume":"41","author":"Roselli","year":"2022","journal-title":"Neurourol\u00a0Urodyn"},{"key":"10.1016\/j.urology.2024.09.051_bib24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1186\/s12889-016-3621-9","article-title":"Examining health literacy disparities in the United States: a third look at the National Assessment of Adult Literacy (NAAL)","volume":"16","author":"Rikard","year":"2016","journal-title":"BMC Public Health"},{"key":"10.1016\/j.urology.2024.09.051_bib25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cardfail.2010.09.016","article-title":"Racial disparities in health literacy and access to care among patients with heart failure","volume":"17","author":"Chaudhry","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.urology.2024.09.051_bib26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.urology.2018.12.021","article-title":"Prevalence, risk factors, and treatment for overactive bladder in a racially diverse population","volume":"126","author":"Mckellar","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.09.051_bib27","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2024.09.051_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/0145721716683811","article-title":"Culturally targeted strategies for diabetes prevention in minority populations: a systematic review and framework","volume":"43","author":"Lagisetty","year":"2017","journal-title":"Diabetes Educ"},{"key":"10.1016\/j.urology.2024.09.051_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.7812\/TPP\/15-052","article-title":"Population care management and team-based approach to reduce racial disparities among African Americans\/Blacks with hypertension","volume":"20","author":"Bartolome","year":"2016","journal-title":"Perm J"},{"key":"10.1016\/j.urology.2024.09.051_bib30","first-page":"779","article-title":"Use of third line therapy for overactive bladder in a practice with multiple subspecialty providers\u2014are we doing enough?","volume":"199","author":"Moskowitz","year":"2018","journal-title":"J\u00a0Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524008495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524008495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T15:01:44Z","timestamp":1733324504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429524008495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":30,"alternative-id":["S0090429524008495"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2024.09.051","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in Advanced Therapeutic Modalities for Overactive Bladder in the United States by Race","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2024.09.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}